11:48 AM EDT, 07/15/2024 (MT Newswires) -- Checkpoint Therapeutics ( CKPT ) and GC Cell said Monday they have entered into a partnership to investigate the combined therapeutic potential of Checkpoint's cosibelimab and GC Cell's Immuncell-LC.

The partnership will begin with in vitro studies to assess the synergistic effects of these therapies on cancer cell destruction. Positive preliminary results could lead to further in vivo research and clinical trials, the companies said.

The combination aims to enhance immune responses against cancer through cosibelimab's antibody-dependent cellular cytotoxicity and Immuncell-LC's cytokine induced killer T cell therapy, according to the combined statement.

Checkpoint shares rose 8.5% in recent trading.

Price: 2.55, Change: +0.20, Percent Change: +8.51